Hansa Biopharma year-end report 2021
Post Views: 240 Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for 2021. Highlights for the fourth quarter 2021 Commercial launch and market access efforts for Idefirix® in Europe are progressing as planned. Reimbursement has been secured in Sweden and the Netherlands,…